Loading
A phase 3 trial in colorectal cancer, run by Erasmus Medical Center, now recruiting.
ctDNA-Based Adjuvant Chemotherapy for High-Risk Rectal Cancer is a phase 3, randomised interventional study registered as NCT07188025 by Erasmus Medical Center, with a registry enrolment figure of 103 participants, started 2025-10-14 and due to reach its primary completion in 2030-10. Interventions recorded: Adjuvant chemotherapy. Conditions listed: Rectal Cancer. Primary outcome: Disease-free survival, intention-to-treat. Colorectal eligibility wording from the registry: "* Histological confirmed rectal cancer; either treated with neoadjuvant (chemo)radiotherapy, and/or clinical/pathological T3/T4 and/or N+ in case no neoadjuvant therapy was administered". Sites: Netherlands. No results are recorded here; the registry entry is the source.
Shares MRD / molecular residual disease testing, Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares MRD / molecular residual disease testing, Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares MRD / molecular residual disease testing, Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares MRD / molecular residual disease testing, Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares MRD / molecular residual disease testing, Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares MRD / molecular residual disease testing, Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares MRD / molecular residual disease testing, Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.